Lucid Diagnostics Inc. (LUCD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 8, 2026
Current Price
$1.03
Price Target
$2.50
Target Range
$2.00 — $3.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-1.0x
Forward PEG—
Implied Growth+99.8%
Median Target$2.50
Analyst Spread40.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$2
+94.2%
Consensus
$3
+142.7%
Bull Case
$3
+191.3%
LUCD Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Lucid Diagnostics Inc. (LUCD) has a Wall Street consensus price target of $2.50, based on estimates from 5 covering analysts. With the stock currently trading at $1.03, this represents a potential upside of +142.7%. The company has a market capitalization of $135M.
Analyst price targets range from a low of $2.00 to a high of $3.00, representing a 40% spread in expectations. The median target of $2.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LUCD trades at a trailing P/E of -1.0x. Analysts expect EPS to grow +99.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+184.7%
Avg Forward P/E159.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GKOSGlaukos Corporation | $7.8B | $133.52 | $146.67 | +9.8% | Buy | — | 24 |
 NVCRNovoCure Limited | $2.0B | $17.89 | $33.50 | +87.3% | Buy | — | 15 |
 NNOXNano-X Imaging Ltd. | $113M | $1.73 | $18.00 | +940.5% | Buy | — | 5 |
 CDXSCodexis, Inc. | $259M | $2.85 | $5.00 | +75.4% | Buy | — | 14 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 NTRANatera, Inc. | $27.5B | $194.24 | $265.63 | +36.8% | Buy | — | 27 |
 GUTSFractyl Health, Inc. Common Stock | $116M | $0.75 | $5.00 | +562.5% | Buy | — | 3 |
 MDTMedtronic plc | $97.6B | $76.15 | $109.50 | +43.8% | Buy | 13.8x | 49 |
 BSXBoston Scientific Corporation | $80.1B | $53.93 | $91.33 | +69.3% | Buy | 16.0x | 43 |
 EWEdwards Lifesciences Corporation | $46.1B | $79.96 | $97.08 | +21.4% | Buy | 26.6x | 48 |
Upside Potential Comparison
NNOXGUTSNVCRCDXSBSXMDTNTRAEWSee LUCD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LUCD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LUCD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLUCD — Frequently Asked Questions
Quick answers to the most common questions about buying LUCD stock.
What is the LUCD stock price target for 2026?
The consensus Wall Street price target for LUCD is $2.5, representing 142.7% upside from the current price of $1.03. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is LUCD a buy, sell, or hold?
LUCD has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $2.5 implies 142.7% upside from current levels.
Is LUCD stock overvalued or undervalued?
LUCD's current price is $1.03 with a consensus target of $2.5 (142.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can LUCD stock go?
The most bullish Wall Street analyst has a price target of $3 for LUCD, while the most conservative target is $2. The consensus of $2.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover LUCD stock?
LUCD is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the LUCD stock forecast?
The 12-month LUCD stock forecast based on 5 Wall Street analysts shows a consensus price target of $2.5, with estimates ranging from $2 (bear case) to $3 (bull case). The median consensus rating is "Buy".
Should I buy LUCD stock?
Wall Street analysts are very optimistic on LUCD, with a "Buy" consensus rating and $2.5 price target (142.7% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do LUCD price targets vary so much?
LUCD analyst price targets range from $2 to $3, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2.5 consensus represents the middle ground.